asg-5me
mAbexperimentalADC
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2010 (NCT01166490)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Choline transporter-like protein 4BINDING AGENT
SLC44A4 binding agent
- Choline transporter-like protein 4INHIBITOR
SLC44A4 inhibitor
- TubulinINHIBITOR
Tubulin inhibitor
Beta tubulin vinca binding domain
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Monomethylauristatin E
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109574 ↗
Also known as
- asg-5me
- asg-5me
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01228760 | Phase 1 | Oct 1, 2010 | Agensys, Inc., Astellas, Seattle Genetics |
| NCT01166490 | Phase 1 | Jul 1, 2010 | Agensys, Inc., Seattle Genetics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Agensys, Inc. | For profit | 2 | 0 | 1 | 2010 |
| Seattle Genetics | For profit | 2 | 1 | 1 | 2010 |
| Astellas | For profit | 1 | 1 | 1 | 2010 |
3 organizations
Page 1 / 1